New drug combo shows promise for colorectal cancer maintenance
NCT ID NCT05775900
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 35 times
Summary
This early-phase study tested a new dosing schedule of cetuximab combined with capecitabine as maintenance therapy for people with a specific type of metastatic colorectal cancer (KRAS/BRAF wild-type). The study involved 24 participants and aimed to find the safest dose and understand how the drug behaves in the body. While it explored effectiveness, the main focus was on safety and drug levels, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.